FindMyKOL
Clinical trialNCT01609062TerminatedPhase 2Interventional

Safety and Exercise Study of Two Doses of BMN 110 for Morquio A Syndrome

SponsorBioMarin PharmaceuticalEnrollment25MPS IVAMorquio A SyndromeMucopolysaccharidosis IVA
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The primary objective of this study was to evaluate the safety of a 2.0 mg/kg/week and a 4.0 mg/kg/week of BMN 110 in patients with Morquio A syndrome for up to 196 weeks. Secondary objectives were to investigate the effect of the two doses on exercise capacity for up to 196 weeks. In addition, the pharmacokinetic (PK) parameters of both doses of BMN 110 was assessed.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

11 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Canada
  • Facility name not stated

    Calgary, Alberta, Canada

  • Facility name not stated

    Toronto, Ontario, Canada

  • Facility name not stated

    Montreal, Quebec, Canada

  • Facility name not stated

    Sherbrook, Quebec, Canada

Germany
  • Facility name not stated

    Hamburg, Germany

United Kingdom
  • Facility name not stated

    Belfast, Northern Ireland, United Kingdom

  • Facility name not stated

    Manchester, United Kingdom

United States
  • Facility name not stated

    Oakland, California, United States

  • Facility name not stated

    Chicago, Illinois, United States

  • Facility name not stated

    New York, New York, United States

  • Facility name not stated

    Houston, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

BMN 110
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
30 Apr 2012
Primary completion
30 Nov 2014
Completion
30 Nov 2014
Last update posted
1 Feb 2016
Registered enrollment
25
Registry id
NCT01609062

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 11 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.